46.17
+0.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alkermes Plc
From its filings with the US Securities and Exchange Commission
Alkermes Plc is based in Dublin 4, Ireland. Its shares trade on Nasdaq under the ticker ALKS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.48bn and net income of $241.7m. At that date it held total assets of $2.49bn and shareholders' equity of $1.82bn.
We have developed and now commercialize products designed to help address the unmet needs of people living with opioid dependence, alcohol dependence, schizophrenia and bipolar I disorder. See the section entitled “Patents and Proprietary Rights” in “Item 1—Business” in this Annual Report for information with respect to the IP protection for our proprietary products.
ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA utilizes our proprietary LINKERX technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is available in four dose strengths with once-monthly dosing options (441 mg, 662 mg and 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 mg). ARISTADA is packaged in a ready-to-use, pre-filled syringe product format. We exclusively manufacture and commercialize ARISTADA in the U.S.
ARISTADA INITIO (aripiprazole lauroxil) leverages our proprietary LINKERX and NANOCRYSTAL technologies and provides an extended-release formulation of aripiprazole lauroxil in a smaller particle size compared to ARISTADA, thereby enabling faster dissolution and more rapid achievement of relevant levels of aripiprazole in the body. ARISTADA INITIO, combined with a single 30 mg dose of oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jul 1991
- Employees
- 2,050
- Website
- alkermes.com ↗
- Head office
- CONNAUGHT HOUSE, DUBLIN 4, L2, 00000
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Richard PopsChairman of the Board, Chief Executive Officer, since 2011$10.1m
- Mr. Blair JacksonInterim Principal Financial Officer, Chief Operating Officer, Executive Vice President, Chief Risk Officer$4.9m
- Mr. Joshua ReedChief Financial Officer, Senior Vice President
- Mr. David GaffinExecutive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary$4.1m
- Dr. Craig HopkinsonExecutive Vice President, Research and Development and Chief Medical Officer$4.3m
- Mr. C. Todd NicholsSenior Vice President, Chief Commercial Officer$3.3m
- Mr. Frank WilsonLead Independent Director$525,164
- Mr. Shane CookeIndependent Director, since 2011$462,140
- Dr. Richard GaynorIndependent Director$473,994
- Dr. Cato LaurencinIndependent Director$460,164
- Ms. Nancy LurkerIndependent Director$1.1m
- Mr. Brian MckeonIndependent Director$483,164
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 84
- Social
- 99
- Governance
- 17
- Direct emissions (scope 1)
- 15,279.8 t
- Energy emissions (scope 2)
- 17,031.63 t
- Women in the workforce
- 48%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alkermes Plc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company boasts a diverse portfolio of innovative products that cater to a wide range of therapeutic areas, allowing it to serve a large customer base. This variety helps maintain a competitive edge and adaptability in the ever-evolving market.
- Additionally, Alkermes Plc benefits from a strong research and development team, enabling it to continually pursue breakthrough drug discoveries and advancements. This emphasis on research and development fosters a culture of innovation and positions the company to capitalize on emerging trends and medical needs.
Weaknesses
- Despite its strengths, Alkermes Plc also faces certain weaknesses that warrant consideration. One of the main challenges is its dependence on a limited number of major customers. This reliance on a few key clients can expose the company to significant revenue fluctuations and vulnerability in the event of contract terminations or changes in purchasing patterns.
- Furthermore, Alkermes Plc operates in a highly regulated industry, subject to stringent approval processes and increasing pressure to demonstrate product safety and efficacy. Adhering to these regulations can be costly, time-consuming, and may prolong the time it takes for new products to enter the market, potentially impacting revenue and market share.
Opportunities
- Alkermes Plc has several promising opportunities to capitalize on. Firstly, the global pharmaceutical market continues to grow, driven by an aging population, increased healthcare spending, and rising demand for novel therapeutic solutions. By leveraging its extensive research capabilities, Alkermes Plc can introduce new products and expand its market reach to capitalize on this growth.
- Additionally, the company can explore strategic partnerships and collaborations with other pharmaceutical firms or healthcare providers to enhance its product offerings and distribution channels. Such alliances can help maximize market penetration, accelerate regulatory approvals, and potentially reduce costs through shared resources and expertise.
Threats
- Alkermes Plc must remain vigilant of potential threats that could impact its future prospects. One significant threat is the intense competition in the pharmaceutical industry, with numerous established players and emerging biotechnology companies vying for market share and investment. This competition can potentially hinder pricing power and limit the company's ability to attract and retain customers.
- Another threat stems from the rapid advancements in technology and scientific research, which may render existing products or treatment methods obsolete. It is crucial for Alkermes Plc to stay at the forefront of these developments to ensure its offerings remain relevant and competitive in the evolving healthcare landscape.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.